semaglutide oral fda approval Wegovy approved for obesity management by on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) New Semaglutide Dosage Forms Approved

Potency, sterility, and stability may vary

10% Experience Dizziness According to NP2GO, approximately 10% of patients experience dizziness when taking semaglutide, and early reports also note that dizziness was reported in 5% of patients during the first month of treatment, highlighting that early monitoring and simple adjustments often prevent escalation

This delivers the same total milligram dose but spreads the peak drug levels more evenly

The most common side effects of all five FDA-approved drugs include: Nausea Vomiting Diarrhea or constipation Stomach pain Other side effects that may occur include: Indigestion Gas/burping Bloating Tiredness Low blood sugar Decreased appetite Hair loss Injection site reactions (not applicable to Rybelsus, which is taken by mouth) Symptoms of a serious allergic reaction, such as hives, trouble breathing, or swelling of the face, lips, tongue, or throat, require emergency medical help

This may involve specific protocols to optimize natural production or, if necessary, medically supervised Hormone Replacement Therapy (HRT) to return your levels to a healthy range

Eating several smaller meals and snacks throughout the day is usually preferable to eating a few bigger meals